Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

GE to Expand in Biomedical and Life Sciences with Strategic Acquisitions from Thermo Fisher Scientific

By BiotechDaily International staff writers
Posted on 15 Jan 2014
General Electric (GE; Fairfield, CT, USA) and Thermo Fisher Scientific (Waltham, MA, USA) have entered into an agreement for GE’s subsidiary GE Healthcare (Little Chalfont, UK) to acquire cell culture media and sera, gene modulation, and magnetic beads businesses from Thermo Fisher for approximately USD 1.06 billion. The three businesses to be acquired generated combined annual revenues of approximately USD 250 million in 2013.

GE Healthcare’s leadership in medical diagnostic technology includes its USD 4 billion life sciences business. The acquisition, anticipated to close in early 2014 (subject to regulatory approvals), will allow GE to expand its offering and development of technologies for the discovery and manufacturing of innovative new medicines, cell therapies, vaccines, and diagnostics in the biomedical sector of its growing life sciences division. It will also extend GE’s bioprocessing manufacturing footprint in Asia, the Americas, and Europe.

Thermo Fisher’s HyClone cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services. Thermo Fisher’s gene modulation technologies complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line extends GE’s existing technologies in protein analysis and medical diagnostics. The complementary product offerings and strong strategic fit of the acquisitions will also enable GE Healthcare to expand and accelerate the development of new “end-to-end” technologies.

“Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal [...] will help us realize our vision of bringing better healthcare to more people at lower cost,” said John Dineen, president and CEO, GE Healthcare.

“We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business,” said Kieran Murphy, president and CEO of GE Healthcare’s life sciences division. “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera.”

Related Links:
General Electric
GE Healthcare
Thermo Fisher Scientific


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.